Heather M. Schneider is a partner in the Intellectual Property Department and President-Elect of the New York Intellectual Property Association. Ms. Schneider's practice focuses on patent litigation, trademark prosecution, transactional work, and antitrust issues involving intellectual property. Her litigation experience encompasses numerous technologies, including pharmaceuticals and biologic products, computer software, medical devices, and chemical products. Her transactional experience includes client counseling on patent and software issues, including licensing, development and collaboration agreements, mergers, and bankruptcy. Heather is working on numerous confidential matters evaluating patents for companies developing vaccines and biosimilars, including patents directed to proteins, cell culture media, polynucleotides, vectors, host cells, and production methods.
In the pharmaceutical field, Heather has played a significant role in a recent collaboration agreement regarding a promising COVID-19 treatment and in litigations and appeals for major life sciences companies involving drug products including: erythropoietin (Epogen), dexmedetomidine (Precedex), rotigotine (Neupro), fingolimod (Gilenya), paricalcitol (Zemplar), oxycodone HCI (OxyContin), argatroban (Argatroban Injection), and amlodipine besylate (Norvasc). She was lead counsel in obtaining a preliminary injunction for breach of contract and other claims for a matter involving agricultural fertilizers. In the computer field, Heather appeared before the U.S. and Canadian courts in the Nortel bankruptcy litigation involving the allocation of proceeds from the sale of Nortel's $4.5 billion portfolio of telecommunications patents.